Holistic Planning LLC Grows Holdings in Pfizer Inc. (NYSE:PFE)

Holistic Planning LLC grew its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 215.8% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 46,364 shares of the biopharmaceutical company's stock after buying an additional 31,681 shares during the period. Holistic Planning LLC's holdings in Pfizer were worth $1,342,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in PFE. Olistico Wealth LLC purchased a new position in Pfizer during the second quarter worth about $25,000. MFA Wealth Advisors LLC purchased a new position in Pfizer during the second quarter worth about $29,000. Quarry LP purchased a new position in Pfizer during the second quarter worth about $31,000. Financial Connections Group Inc. purchased a new position in Pfizer during the second quarter worth about $34,000. Finally, ESL Trust Services LLC purchased a new position in Pfizer during the first quarter worth about $37,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of the business's stock in a transaction dated Wednesday, October 30th. The shares were acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 0.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.06% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on PFE. Cantor Fitzgerald reissued an "overweight" rating and set a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. Sanford C. Bernstein initiated coverage on shares of Pfizer in a report on Thursday, October 17th. They issued a "market perform" rating and a $32.00 target price for the company. Evercore ISI raised shares of Pfizer to a "strong-buy" rating in a report on Wednesday, October 30th. Wells Fargo & Company increased their target price on shares of Pfizer from $28.00 to $30.00 and gave the company an "equal weight" rating in a report on Wednesday, July 31st. Finally, Barclays increased their target price on shares of Pfizer from $30.00 to $32.00 and gave the company an "equal weight" rating in a report on Wednesday, July 31st. Eight analysts have rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $33.58.

Pfizer Price Performance

Shares of PFE stock traded down $0.32 during trading hours on Friday, hitting $26.72. The company's stock had a trading volume of 55,951,315 shares, compared to its average volume of 37,583,031. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $31.54. The business has a fifty day moving average of $28.89 and a 200-day moving average of $28.63. The stock has a market cap of $151.42 billion, a price-to-earnings ratio of 36.11, a P/E/G ratio of 0.87 and a beta of 0.67. The company has a current ratio of 1.00, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same quarter last year, the business earned ($0.17) earnings per share. Pfizer's revenue was up 31.2% compared to the same quarter last year. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be issued a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.29%. Pfizer's dividend payout ratio (DPR) is presently 227.03%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.